For the past decade, Erbitux-based regimens have been the mainstay of treatment for recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the head and neck (SCCHN), but the launches of Merck & Co.’s Keytruda and Bristol Myers Squibb’s Opdivo are transforming the SCCHN treatment algorithm. However, despite the label expansions of these immune checkpoint inhibitors to include recurrent or metastatic non-nasopharyngeal SCCHN, more-efficacious first-line treatment options are needed to address the unmet needs pertaining to this subpopulation of SCCHN.
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European medical oncologists fielded in February 2021
Key companies: Merck & Co., Bristol Myers Squibb, Eli Lilly
Key drugs: Erbitux, Keytruda, Opdivo